Raymond James Financial Inc. Makes New Investment in Enovis Co. (NYSE:ENOV)

Raymond James Financial Inc. purchased a new position in Enovis Co. (NYSE:ENOV - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 373,911 shares of the company's stock, valued at approximately $16,407,000. Raymond James Financial Inc. owned approximately 0.66% of Enovis as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also modified their holdings of the business. UMB Bank n.a. grew its position in Enovis by 128.2% during the 4th quarter. UMB Bank n.a. now owns 778 shares of the company's stock worth $34,000 after purchasing an additional 437 shares during the last quarter. Pinnacle Bancorp Inc. increased its position in shares of Enovis by 54.5% in the 4th quarter. Pinnacle Bancorp Inc. now owns 850 shares of the company's stock valued at $37,000 after acquiring an additional 300 shares during the period. FMR LLC raised its stake in Enovis by 20.5% in the 3rd quarter. FMR LLC now owns 2,840 shares of the company's stock worth $122,000 after acquiring an additional 484 shares during the last quarter. XTX Topco Ltd acquired a new stake in Enovis during the 3rd quarter worth about $217,000. Finally, Legacy Capital Wealth Partners LLC purchased a new stake in Enovis during the 4th quarter valued at about $228,000. Hedge funds and other institutional investors own 98.45% of the company's stock.

Enovis Stock Performance

ENOV traded down $0.23 during midday trading on Friday, hitting $39.12. 1,073,328 shares of the company were exchanged, compared to its average volume of 669,771. The company's 50 day simple moving average is $42.84 and its 200 day simple moving average is $43.56. The firm has a market capitalization of $2.23 billion, a price-to-earnings ratio of -17.86 and a beta of 2.05. Enovis Co. has a 1-year low of $35.14 and a 1-year high of $62.79. The company has a current ratio of 2.27, a quick ratio of 1.12 and a debt-to-equity ratio of 0.40.

Remove Ads

Enovis (NYSE:ENOV - Get Free Report) last posted its earnings results on Wednesday, February 26th. The company reported $0.98 EPS for the quarter, topping the consensus estimate of $0.92 by $0.06. Enovis had a positive return on equity of 4.39% and a negative net margin of 5.95%. The firm had revenue of $560.98 million for the quarter, compared to analyst estimates of $555.14 million. As a group, sell-side analysts predict that Enovis Co. will post 2.79 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, Needham & Company LLC decreased their target price on Enovis from $65.00 to $64.00 and set a "buy" rating for the company in a report on Thursday, February 27th.

Enovis Company Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.